Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
0.8150
+0.0001 (0.01%)
May 9, 2025, 10:43 AM - Market open

Company Description

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company.

The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases.

It focuses on developing traditional therapies and psychedelic treatments in formulations. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief.

In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).

The company’s research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore.

The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020.

Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Silo Pharma, Inc.
Silo Pharma logo
Country United States
Founded 2010
Industry Biotechnology
Sector Healthcare
Employees 3
CEO Eric Weisblum

Contact Details

Address:
677 North Washington Boulevard
Sarasota, Florida 34236
United States
Phone 718 400 9031
Website silopharma.com

Stock Details

Ticker Symbol SILO
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001514183
CUSIP Number 82711P102
ISIN Number US82711P2011
Employer ID 46-2137136
SIC Code 2834

Key Executives

Name Position
Eric Weisblum Chairman, President and Chief Executive Officer

Latest SEC Filings

Date Type Title
Apr 29, 2025 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 25, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Apr 11, 2025 DRS [Cover] Draft Registration Statement
Apr 4, 2025 424B3 Prospectus
Apr 3, 2025 EFFECT Notice of Effectiveness
Mar 28, 2025 POS AM Post-Effective amendments for registration statement
Mar 28, 2025 10-K Annual Report
Mar 10, 2025 8-K Current Report
Mar 7, 2025 8-K Current Report
Feb 13, 2025 SCHEDULE 13G/A Filing